Driving impairment
This medicine may affect your ability to drive or use machines.
Leaflet FLUORORINIL 0.1% / 0.05% inhalation suspension
- Product code:
- W02161001
- Quantity:
- 10
- Indicated for:
- allergic rhinitis; urticaria
- Route of administration:
- inhalation
- Substance:
- chlorpheniramine maleate + betamethasone (antiallergic agent + glucocorticoid)
- ATC
- R01ADN1 — Respiratory system | Decongestants and other nasal preparations for topical use | Corticosteroids
Precautions:
Glaucoma warning
Use caution if you have glaucoma or increased eye pressure.
Anticholinergic effects
May cause dry mouth, constipation, urinary retention, or blurred vision.
Hyperglycemia
This medicine may increase blood sugar.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Withdrawal / do not stop abruptly
Do not stop treatment abruptly without medical advice.
Drowsiness / sedation
This medicine may cause drowsiness or reduced alertness.
This combination of chlorpheniramine maleate and betamethasone is used for the treatment of allergic and inflammatory conditions such as allergic rhinitis, urticaria, atopic dermatitis, or other severe allergic reactions. Chlorpheniramine reduces allergic symptoms, while betamethasone combats inflammation and excessive immune responses.
It is taken orally as directed by a doctor, usually in tablet form. It is intended for short-term use during acute episodes to minimize the risk of side effects associated with corticosteroids.
Common side effects include drowsiness, dizziness, dry mouth (due to chlorpheniramine), increased appetite, fluid retention, or hyperglycemia (due to betamethasone).
This combination is contraindicated in patients with untreated systemic infections, glaucoma, uncontrolled diabetes, or severe hypertension. It should be used with caution in children, as corticosteroids may affect growth.
Patients should strictly follow their doctor’s instructions and avoid alcohol consumption, which may enhance the sedative effects of chlorpheniramine.
It is taken orally as directed by a doctor, usually in tablet form. It is intended for short-term use during acute episodes to minimize the risk of side effects associated with corticosteroids.
Common side effects include drowsiness, dizziness, dry mouth (due to chlorpheniramine), increased appetite, fluid retention, or hyperglycemia (due to betamethasone).
This combination is contraindicated in patients with untreated systemic infections, glaucoma, uncontrolled diabetes, or severe hypertension. It should be used with caution in children, as corticosteroids may affect growth.
Patients should strictly follow their doctor’s instructions and avoid alcohol consumption, which may enhance the sedative effects of chlorpheniramine.
General data about FLUORORINIL 0.1% / 0.05%
- Substance:
- chlorpheniramine maleate + betamethasone
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W02161001
- Concentration:
- 0.1% / 0.05%
- Pharmaceutical form:
- inhalation suspension
- Quantity:
- 10
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.